PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma
- PMID: 19416634
- DOI: 10.1016/j.phrs.2009.01.018
PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma
Abstract
Glucocorticoids (GCs) are effective anti-inflammatory agents widely used in therapeutic approach to treatment of spinal cord trauma. Previous results suggest that peroxisome proliferator activated receptor alpha (PPAR-alpha), an intracellular transcription factor activated by fatty acids, plays a role in control of secondary inflammatory process associated with spinal cord injury (SCI). With the aim to characterize the role of PPAR-alpha in GC-mediated anti-inflammatory activity, we tested the efficacy of dexamethasone (DEX), a synthetic GC specific for glucocorticoid receptor (GR), in an experimental model of spinal cord trauma induced in mice by the application of vascular clips (force of 24 g) to the dura via a four-level T5-T8 laminectomy, and comparing mice lacking PPAR-alpha (PPAR-alphaKO) with wild type (WT) mice. Results indicate that DEX-mediated anti-inflammatory activity is weakened in PPAR-alphaKO mice, as compared to WT controls. In particular, DEX was less effective in PPAR-alphaKO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation and tissue injury, neutrophil infiltration, nitrotyrosine formation, pro-inflammatory cytokine expression, NF-kappaB activation, inducible nitric-oxide synthase (iNOS) expression; and apoptosis. This study indicates that PPAR-alpha can contribute to the anti-inflammatory activity of GCs in SCI.
Similar articles
-
Combination of dexamethasone and etanercept reduces secondary damage in experimental spinal cord trauma.Neuroscience. 2007 Nov 30;150(1):168-81. doi: 10.1016/j.neuroscience.2007.06.059. Epub 2007 Aug 2. Neuroscience. 2007. PMID: 17945432
-
PPAR-α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury.Mol Neurobiol. 2017 Oct;54(8):5973-5987. doi: 10.1007/s12035-016-0131-9. Epub 2016 Sep 29. Mol Neurobiol. 2017. Retraction in: Mol Neurobiol. 2024 Jul;61(7):4924. doi: 10.1007/s12035-024-04164-x. PMID: 27686077 Retracted.
-
Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids.Mol Pharmacol. 2008 Feb;73(2):323-37. doi: 10.1124/mol.107.041475. Epub 2007 Nov 5. Mol Pharmacol. 2008. PMID: 17984196
-
Current Agents and Related Therapeutic Targets for Inflammation After Acute Traumatic Spinal Cord Injury.World Neurosurg. 2019 Dec;132:138-147. doi: 10.1016/j.wneu.2019.08.108. Epub 2019 Aug 27. World Neurosurg. 2019. PMID: 31470153 Review.
-
Modulating inflammatory cell responses to spinal cord injury: all in good time.J Neurotrauma. 2014 Nov 1;31(21):1753-66. doi: 10.1089/neu.2014.3429. Epub 2014 Sep 8. J Neurotrauma. 2014. PMID: 24934600 Review.
Cited by
-
Interactions between nuclear receptors glucocorticoid receptor α and peroxisome proliferator-activated receptor α form a negative feedback loop.Rev Endocr Metab Disord. 2022 Oct;23(5):893-903. doi: 10.1007/s11154-022-09725-w. Epub 2022 Apr 27. Rev Endocr Metab Disord. 2022. PMID: 35476174 Review.
-
PPARα agonist relieves spinal cord injury in rats by activating Nrf2/HO-1 via the Raf-1/MEK/ERK pathway.Aging (Albany NY). 2021 Nov 19;13(22):24640-24654. doi: 10.18632/aging.203699. Epub 2021 Nov 19. Aging (Albany NY). 2021. PMID: 34799468 Free PMC article.
-
Metabolic reprogramming: a new option for the treatment of spinal cord injury.Neural Regen Res. 2025 Apr 1;20(4):1042-1057. doi: 10.4103/NRR.NRR-D-23-01604. Epub 2024 Apr 3. Neural Regen Res. 2025. PMID: 38989936 Free PMC article.
-
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.Mediators Inflamm. 2013;2013:328797. doi: 10.1155/2013/328797. Epub 2013 Feb 25. Mediators Inflamm. 2013. PMID: 23533304 Free PMC article.
-
B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury.Neurotherapeutics. 2016 Oct;13(4):880-894. doi: 10.1007/s13311-016-0446-2. Neurotherapeutics. 2016. PMID: 27215219 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous